PT  - JOURNAL ARTICLE
AU  - Karimian, Mohammad
AU  - Jamshidbeigi, Amirreza
AU  - Badfar, Gholamreza
AU  - Azami, Milad
TI  - Laboratory findings in coronavirus disease 2019 (COVID-19) patients: a comprehensive systematic review and meta-analysis
AID  - 10.1101/2020.06.07.20124602
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.07.20124602
4099  - http://medrxiv.org/content/early/2020/06/08/2020.06.07.20124602.short
4100  - http://medrxiv.org/content/early/2020/06/08/2020.06.07.20124602.full
AB  - Background In early December 2019, the first patient with COVID-19 pneumonia was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 patients.Data Sources PubMed/Medline, Scopus, EMBASE, Web of Science (ISI), Cochrane Library, Ovid, Science Direct, CINAHL and EBSCO.Study Selection Cross-sectional of adverse outcomes stratified by the status of ICLs were selected.Data Extraction The prevalence of available variables for laboratory tests were extracted.Results Finally, 52 studies involving 5490 patients with COVID-19 entered the meta-analysis process. The prevalence of leukopenia, lymphopenia, elevated c-reactive protein (CRP), elevated erythrocyte sedimentation rate (ESR), elevated serum amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence of elevated interleukin-6 was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 was 62.0% (95%CI: 51.1-71.6), reduced CD8 was 42.7% (95%CI: 32.2-53.9). The prevalence of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide (BNP) was 48.9% (95%CI: 30.4-67.7), elevated blood urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6).Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19. The results show that lymphopenia, elevated CRP, elevated ESR, elevated ferritin, elevated serum amyloid A, elevated BNP, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4, reduced CD8, elevated D-dimer, reduced PT, elevated interleukin-2, elevated interleukin-6, elevated LDH and hyperglycemia are the common findings at the time of admission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Ilam University of Medical sciences. Funder role was only financial support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable.COVID-19Coronavirus disease 2019ARDSAcute respiratory distress syndromeSARS-CoV-2Severe acute respiratory syndrome coronavirus 2SARS-CoVSevere acute respiratory syndrome coronavirusMERS-COVMiddle East respiratory syndrome coronavirusWHOworld health organizationPHEICPublic health emergency of international concernPRISMAPreferred Reporting Items for Systematic Reviews and Meta-analysisCIConfidence intervalICUintensive care unitNOSNewcastle-Ottawa ScaleCMAComprehensive Meta-Analysis SoftwareCRPc-reactive proteinESRerythrocyte sedimentation ratePCTprocalcitonincTnItroponin-ICKMBcreatine kinase-MBBNPbrain natriuretic peptideBUNblood urea nitrogenALTalanine aminotransferaseASTaspartate aminotransferaseLDHlactate dehydrogenaseCPKcreatine phosphokinasePTprothrombin timePTTpartial thromboplastin timeMODSmultiple organ dysfunction syndromeACEAngiotensin converting enzymeDPP-IVdipeptidyl peptidase IVAKIacute kidney injuryDICDisseminated intravascular coagulation